Does the Lipid-Lowering Peroxisome Proliferator-Activated Receptors Ligand Bezafibrate Prevent Colon Cancer in Patients With Coronary Artery Disease?

Cardiovascular Diabetology - United Kingdom
doi 10.1186/1475-2840-7-18
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Peroxisome Proliferator-Activated Receptors Associated With Nonalcoholic Fatty Liver Disease

PPAR Research
Drug DiscoveryPharmacology
2017English

Peroxisome Proliferator-Activated Receptors (Ppars) in Health and Disease.

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
BiochemistryMedicineGeneticsMolecular Biology
2002English

Drugs and the Peroxisome Proliferator Activated Receptors

2014English

Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2002English

Peroxisome Proliferator-Activated Receptors in HCV-Related Infection

PPAR Research
Drug DiscoveryPharmacology
2009English

Peroxisome Proliferator-Activated Receptor Alpha Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease

Circulation
Cardiovascular MedicinePhysiologyCardiology
2002English

Peroxisome Proliferator-Activated Receptors and Hepatitis C Virus

Therapeutic Advances in Gastroenterology
Gastroenterology
2011English

Peroxisome-Proliferator-Activated Receptors (PPARs) Are Potential Drug Targets for Cancer Therapy

Oncotarget
Oncology
2017English

Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease

Journal of Vascular Surgery
SurgeryCardiovascular MedicineCardiology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy